Exagen (NASDAQ:XGN – Get Free Report) and Bio-Rad Laboratories (NYSE:BIO – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Insider and Institutional Ownership
75.3% of Exagen shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Exagen and Bio-Rad Laboratories”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exagen | $66.57 million | 1.69 | -$19.95 million | ($0.89) | -5.25 |
| Bio-Rad Laboratories | $2.58 billion | 2.96 | $759.90 million | $6.07 | 47.03 |
Bio-Rad Laboratories has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Exagen and Bio-Rad Laboratories, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exagen | 1 | 0 | 8 | 0 | 2.78 |
| Bio-Rad Laboratories | 1 | 3 | 1 | 0 | 2.00 |
Exagen presently has a consensus price target of $9.25, indicating a potential upside of 98.07%. Bio-Rad Laboratories has a consensus price target of $303.33, indicating a potential upside of 6.25%. Given Exagen’s stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Bio-Rad Laboratories.
Profitability
This table compares Exagen and Bio-Rad Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exagen | -29.49% | -94.37% | -28.96% |
| Bio-Rad Laboratories | 6.52% | 3.56% | 2.49% |
Risk & Volatility
Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Summary
Bio-Rad Laboratories beats Exagen on 9 of the 14 factors compared between the two stocks.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
